On this week's BioTech Nation, Tech Nation Health Chief Correspondent Dr. Daniel Kraft tells us about the trend of "hospital-at-home". As we see the expansion of remote healthcare technologies, could the future of hospital-like care be as on-demand as a food delivery app?

In time for the 2026 ASCO Annual Meeting in Chicago, we're highlighting 3 BioTech companies shaping the future of cancer treatment...
On this episode of BioTech Nation, Dr. Will Decker and Jay Hartenbach join Moira to talk about Diakonos Oncology's unique approach to cancer immunotherapy. 25 years ago, as a young post-doc, Dr. Decker made a discovery that wasn't in the biology textbooks - and the scientific community was skeptical. But now, after two decades of research and a new drug entering Phase II human trials for Glioblastoma treatment, that discovery could mean a new pathway to treating aggressive cancers...

In time for the 2026 ASCO Annual Meeting in Chicago, we're highlighting 3 BioTech companies shaping the future of cancer treatment...

On this episode of BioTech Nation: how Syndax Pharmaceuticals got two new drugs approved in the last two years, for the treatment of acute myeloid leukemia and graft vs. host disease in both adults and children. CEO Michael Metzger talks to Moira about Syndax's approach to getting the drugs across the finish line, and how they've now set their sights on additional indications and cancer therapies.

In time for the 2026 ASCO Annual Meeting in Chicago, we're highlighting 3 BioTech companies shaping the future of cancer treatment:

On this episode of BioTech Nation, Dan Schmitt of Actuate Therapeutics talks about a new kind of drug showing positive early results in hard-to-treat cancer - including adult pancreatic cancer, and two pediatric cancers. So, what’s next? Global collaborations, international trials, and efforts into different types of cancer…and they’re showing no sign of slowing down.

This week on BioTech Nation, Dr. Jonas Hannestad and Dr. Joanne Taylor of Gain Therapeutics join Moira to discuss a different approach to treating Parkinson's. While treatments are typically focused on relieving symptoms, Gain Therapeutics aims to stop progression of the disease itself.

With the recent passing of Dr. J. Craig Venter, biotech scientist and entrepreneur, we look back at Moira and David Ewing Duncan's 2007 interview with Dr. Venter. The occasion for the interview was the publication of his autobiography: "A Life Decoded: My Genome, My Life." Dr. Craig Venter was known for catalyzing the race to decode the human genome, and at the time of the interview had just decoded his own complete DNA and published it on the Internet.

This week on BioTech Nation, we celebrate the 50th anniversary of Genentech, the first biotech company to go public. Moira speaks with CEO Ashley Magargee about the company's journey over the last 50 years, the evolution of biotech, and where they're headed next.

This week on BioTech Nation, Andrew Farnum and Sarah LeBaron von Baeyer discuss Variant Bio’s unique approach to collecting genetic data - working specifically with indigenous tribes and more isolated populations around the globe. Could compiling this diverse genetic data reveal something about how to develop better drugs and diagnostics? And how might those sharing their data be ethically compensated for it?